GSK 299423
 | |
 | |
| Names | |
|---|---|
| IUPAC name
4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile | |
| Identifiers | |
| ChemSpider | 24751852  |
| |
| Jmol-3D images | Image |
| |
| Properties | |
| Molecular formula |
C25H27N5O2S |
| Molar mass | 461.58 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
verify (what is: / ?) | |
| Infobox references | |
3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB 2xcs.
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.
References
- ↑ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
- ↑ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010
- ↑ Bax BD et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature 466 (7309): 935–40. doi:10.1038/nature09197. PMID 20686482. (primary source)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||